ESTRO Brachytherapy for Prostate Cancer 2018

HDR MONOTHERAPY

• High rates of biochemical control in early years • Optimal indication yet to be defined: ?intermediate/high risk…?low risk

• Acute toxicity short-lived cf LDR BT • Late toxicity profile favourable with low rates of late urinary and erectile dysfunction